Table 1.
Characteristics of the analyzed trials.
| Study | Design | Primary endpoint | Number of Patients Experimental Arm | Number of Patients Control Arm | Experimental drug | Control | Tumor location | Jaded score |
|---|---|---|---|---|---|---|---|---|
| Yao 201110 | III | PFS | 207 | 203 | Everolimus | Placebo | Pancreatic | 5 |
| Raymond11 | III | PFS | 86 | 85 | Sunitinib | Placebo | Pancreatic | 5 |
| Yao 201512 | III | PFS | 205 | 97 | Everolimus | Placebo | Non-pancreatic NETS | 5 |
| Pavel18 | III | PFS | 216 | 213 | Everolimus+Octreotide LAR | Placebo + octreotide LAR | Non-pancreatic NETS | 5 |
| Yao 2015 ASCO19 | III | PFS | 201 | 201 | Bevacizumab+Octereotide | Interferon α-2B+Octereotide | Non-pancreatic NETS | 4 |
| Yao 200820 | II | PFS | 22 | 22 | Bevacizumab | PEG interferon α−2B | Non-pancreatic NETS | 3 |
| Kulke 201521 | II | 75 | 75 | 75 | Everolimus+Bevacizumab | Everolimus | Pancreatic | 3 |